english.prescrire.org > Spotlight > 100 most recent > In the May issue of Prescrire International: Ranibizumab or bevacizumab in AMD?

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent : 1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Spotlight

In the May issue of Prescrire International: Ranibizumab or bevacizumab in AMD?

FREE DOWNLOAD The Italian independent drug bulletin Informazioni sui Farmaci published a review comparing ranibizumab versus bevacizumab for age-related macular degeneration (AMD). Its conclusion differs from that of Prescrire’s review. A letter from Informazioni sui Farmaci's editors and Prescrire's reply explore the various scientific and policy questions surrounding these treatments.

Full text available for free download.

Summary

The Italian independent drug bulletin Informazioni sui Farmaci, a member of the International Society of Drug Bulletins (ISDB), published a review comparing ranibizumab versus bevacizumab for age-related macular degeneration (AMD).
Its conclusion differs from that of Prescrire’s review, published in issue 163 of Prescrire International. Giulio Formoso and Maria Font have offered on behalf of Informazioni sui Farmaci to present their evaluations.
The text available for download below recaps the position of Informazioni sui Farmaci, and includes an English translation of the full article published in the Italian bulletin.
A few points outlining Prescrire’s position, already set out in detail in issue 163 of Prescrire International, are published along with the letter.

Full text available for free download.

"Ranibizumab or bevacizumab in AMD?" Prescrire Int 2016; 25 (171): 132-1 - 132-5 (Pdf, free)

Download the full review
Pdf, free

For more information:

Bevacizumab (Avastin°)
and age-related macular
degeneration.Lower cost
does not justify taking risks
Prescrire Int 2015;
24 (163) : 201-205
Pdf, subscribers only

Age-related macular
degeneration: do not
take risks in order
to cut costs
(September 2015)
Free